<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="a promising platform of oncolytic viruses for use in animal" exact="cancer" post="therapy. Recent advances have revealed that use of the"/>
 <result pre="virus (CDV) is an enveloped negative-RNA virus, which, along with" exact="measles" post="virus (MeV), Rinderpest virus (RPV), peste des petits ruminants"/>
 <result pre="cause a similar pathogenesis characterized by fever, skin rash, and" exact="conjunctivitis" post="with profound immune suppression, but also elicit lifelong immunity"/>
 <result pre="species [11,12,13,14,15]. In addition, CDV can induce apoptosis in many" exact="cancer" post="cell lines, including canine neoplastic lymphocytes, canine adenofibrosarcoma cells,"/>
 <result pre="cell lines, including canine neoplastic lymphocytes, canine adenofibrosarcoma cells, human" exact="breast cancer" post="cells, and human cervical cancer cells. Moreover, persistent infection"/>
 <result pre="lines, including canine neoplastic lymphocytes, canine adenofibrosarcoma cells, human breast" exact="cancer" post="cells, and human cervical cancer cells. Moreover, persistent infection"/>
 <result pre="lymphocytes, canine adenofibrosarcoma cells, human breast cancer cells, and human" exact="cervical cancer" post="cells. Moreover, persistent infection by CDV has been shown"/>
 <result pre="canine adenofibrosarcoma cells, human breast cancer cells, and human cervical" exact="cancer" post="cells. Moreover, persistent infection by CDV has been shown"/>
 <result pre="of the antigenome is generated by autocatalytic cleavage from a" exact="hepatitis" post="delta virus ribozyme (HDV-Rbz) sequence positioned directly downstream of"/>
 <result pre="several disadvantages, primarily high poxvirus-mediated cytotoxicity, challenges associated with separating" exact="vaccinia virus" post="from the rescued viruses, and increasing restrictions on the"/>
 <result pre="the rescued viruses, and increasing restrictions on the use of" exact="vaccinia virus," post="especially for vaccine development. To avoid these possible problems,"/>
 <result pre="spreading of immune cells observed, producing the same levels of" exact="leukopenia" post="and inhibiting lymphocyte proliferation activities as in the case"/>
 <result pre="of vaccinated dogs, but on rare occasions can cause post-vaccination" exact="encephalitis" post="[12]. Although these two vaccines significantly reduced the number"/>
 <result pre="a vector to stably express the glycoprotein (G) of the" exact="rabies" post="virus (RABV) within an additional transcription unit of a"/>
 <result pre="and diseases arising from Rockborn strain infection such as post-vaccination" exact="encephalitis" post="have been stopped by vaccinations [11]. Additionally, the introduction"/>
 <result pre="2% of canines over the age of 10 die from" exact="cancer" post="[76,77,78], with the incidence of breast cancer being high,"/>
 <result pre="of 10 die from cancer [76,77,78], with the incidence of" exact="breast cancer" post="being high, especially in female dogs [79]. Defects in"/>
 <result pre="10 die from cancer [76,77,78], with the incidence of breast" exact="cancer" post="being high, especially in female dogs [79]. Defects in"/>
 <result pre="IFN antiviral response pathway are known to be common in" exact="cancer" post="cells, making them more permissive to viral infections compared"/>
 <result pre="humans and the veterinary field, the utilization of morbillivirus, adenovirus," exact="vaccinia virus," post="coxsackie virus, and reovirus is being extensively investigated and"/>
 <result pre="as they ideally infect, replicate, and induce the lysis of" exact="cancer" post="cells, whereas they do not harm noncancerous cell types."/>
 <result pre="viral progeny are released resulting in the infection of neighboring" exact="cancer" post="cells allowing for the easy spread and escalation of"/>
 <result pre="escalation of the therapy. Oncolytic viruses could be targeted to" exact="cancer" post="cells at several levels, including receptor-dependent viral entry, and"/>
 <result pre="viral replication [88,89,90]. Recently, increasing studies on oncolytic viruses for" exact="cancer" post="treatment have often been focused on engineering the virus"/>
 <result pre="to increase viral specificity and enhance the oncolytic effect to" exact="cancer" post="cells. In 2015, a new drug for oncolytic virotherapy,"/>
 <result pre="a new drug for oncolytic virotherapy, talimogene laherparepvec (IMLYGIC), a" exact="herpes simplex" post="virus, that has been genetically engineered to express granulocyte"/>
 <result pre="therapeutic agents for the clinical treatment of human or animal" exact="cancer" post="patients, major obstacles, including potential viral toxicity, ineffective delivery"/>
 <result pre="agent in anecdotal reports regarding the regression of a Hodgkin" exact="lymphoma" post="following natural MeV infection in humans [101]. Attenuated MeV,"/>
 <result pre="SLAMblind MeV maintained an efficient capacity for infection of human" exact="breast cancer" post="cells, the virus caused no symptoms, including immunosuppression, in"/>
 <result pre="MeV maintained an efficient capacity for infection of human breast" exact="cancer" post="cells, the virus caused no symptoms, including immunosuppression, in"/>
 <result pre="also demonstrated that the SLAMblind MeV could infect canine mammary" exact="cancer" post="cells, displaying antitumor activity in vitro, in xenografts, and"/>
 <result pre="viruses have been reported as oncolytic agents, including adenovirus, reovirus," exact="vaccinia virus," post="and CDV. One advantage of CDV as an oncolytic"/>
 <result pre="able to infect and induce apoptosis in many kinds of" exact="cancer" post="cells (Table 2). Infection of canine lymphoid cell lines,"/>
 <result pre="lymphoid cell lines, including GLGL-90 chronic large granular lymphocytic T-cell" exact="leukemia" post="cells, and 17–71 acute B-cell lymphoma cells, expressing SLAM"/>
 <result pre="large granular lymphocytic T-cell leukemia cells, and 17–71 acute B-cell" exact="lymphoma" post="cells, expressing SLAM on the surface of their cell"/>
 <result pre="the CDV Onderstepoort strain was able to infect canine histiocytic" exact="sarcoma" post="cell lines (CCT and DH82 cells) and induce apoptosis"/>
 <result pre="These results suggest that a CDV infection of canine histiocytic" exact="sarcoma" post="cells could restore the expression of RECK and might"/>
 <result pre="canine mammary tumor cells could be potential candidates for CDV-induced" exact="cancer" post="therapy [17]. 6.3. Safety Issues Associated with CDV-Based Therapeutics"/>
 <result pre="the pathogenic phenotype. As an effective oncolytic virus for canine" exact="cancer" post="cells in vitro, live attenuated CDV strains also maintain"/>
 <result pre="antiviral agents effective against the CDV strains being considered for" exact="cancer" post="treatment. 7. Perspectives and Challenges of Oncolytic CDV Therapy"/>
 <result pre="genetic engineering CDV strains, as an oncolytic virus for canine" exact="cancer" post="patients compared with the advanced progress of human virotherapy"/>
 <result pre="trials, the high similarity between human and canine cancers, including" exact="colorectal cancer," post="fibrosarcoma, osteosarcoma, and soft tissue sarcoma [80,81,82,83,84,85,86,87] could help"/>
 <result pre="canine cancers, including colorectal cancer, fibrosarcoma, osteosarcoma, and soft tissue" exact="sarcoma" post="[80,81,82,83,84,85,86,87] could help translate cases of successful oncolytic virotherapy"/>
 <result pre="use of CDV as oncolytic viruses and therapeutics for canine" exact="cancer" post="patients. Use of genetically engineered viruses through RGS approaches,"/>
 <result pre="In recent studies of two members of the Mononegavirales, vesicular" exact="stomatitis" post="virus (VSV) and MeV-mediated oncolysis, the strategies used to"/>
 <result pre="could also be enhanced to spread the cytopathic effect in" exact="cancer" post="cells compared with CDV alone. Recently, &quot;immunovirotherapy�? strategies to"/>
 <result pre="native anti-tumor immune response. These strategies were used for MeV-susceptible" exact="cancer" post="mouse models and showed significantly-senhanced tumor regression or prolonged"/>
 <result pre="2.WooP.C.LauS.K.WongB.H.FanR.Y.WongA.Y.ZhangA.J.WuY.ChoiG.K.LiK.S.HuiJ.et al.Feline morbillivirus, a previously undescribed paramyxovirus associated with tubulointerstitial" exact="nephritis" post="in domestic catsProc. Natl. Acad. Sci. USA20121095435544010.1073/pnas.111997210922431644 3.UhlE.W.KelderhouseC.BuikstraJ.BlickJ.P.BolonB.HoganR.J.New world"/>
 <result pre="canine distemper virus, the Rockborn strainVaccine2011291222122710.1016/j.vaccine.2010.12.00121167117 12.HartleyW.J.A post-vaccinal inclusion body" exact="encephalitis" post="in dogsVet. Pathol.19741130131210.1177/0300985874011004034156617 13.CarpenterJ.W.AppelM.J.EricksonR.C.NovillaM.N.Fatal vaccine-induced canine distemper virus infection"/>
 <result pre="8 (TNFAIP8) expression associated with cell survival and death in" exact="cancer" post="cell lines infected with canine distemper virusVet. Comp. Oncol.20171533634410.1111/vco.1216826373887"/>
 <result pre="canine mammary tubular adenocarcinoma cellsVet. Comp. Oncol.20191717418310.1111/vco.1246630756476 21.BilleterM.A.NaimH.Y.UdemS.A.Reverse genetics of" exact="measles" post="virus and resulting multivalent recombinant vaccines: Applications of recombinant"/>
 <result pre="measles virus and resulting multivalent recombinant vaccines: Applications of recombinant" exact="measles" post="virusesCurr. Top. Microbiol. Immunol.200932912916219198565 22.SidhuM.S.HusarW.CookS.D.DowlingP.C.UdemS.A.Canine distemper terminal and intergenic"/>
 <result pre="expressionJ. Virol.200882105101051810.1128/JVI.01419-0818753197 31.LiZ.WangJ.YuanD.WangS.SunJ.YiB.HouQ.MaoY.LiuW.A recombinant canine distemper virus expressing a modified" exact="rabies" post="virus glycoprotein induces immune responses in miceVirus Genes20155043444110.1007/s11262-015-1169-x25764477 32.Elroy-SteinO.MossB.Cytoplasmic"/>
 <result pre="35.WangX.FengN.GeJ.ShuaiL.PengL.GaoY.YangS.XiaX.BuZ.Recombinant canine distemper virus serves as bivalent live vaccine against" exact="rabies" post="and canine distemperVaccine2012305067507210.1016/j.vaccine.2012.06.00122698451 36.von MesslingV.MilosevicD.CattaneoR.Tropism illuminated: Lymphocyte-based pathways blazed"/>
 <result pre="strain Snyder Hill expressing green or red fluorescent proteins causes" exact="meningoencephalitis" post="in the ferretJ. Virol.2012867508751910.1128/JVI.06725-1122553334 39.TatsuoH.OnoN.YanagiY.Morbilliviruses use signaling lymphocyte activation"/>
 <result pre="expressing interleukin-7 enhances humoral immunityJ. Gen. Virol.201910060261510.1099/jgv.0.00124730875282 72.RouxelR.N.SvitekN.von MesslingV.A chimeric" exact="measles" post="virus with canine distemper envelope protects ferrets from lethal"/>
 <result pre="recombinant canine distemper virus recovered from cloned DNAsVirus Res.20028313114710.1016/S0168-1702(01)00430-011864746 76.BrayF.FerlayJ.SoerjomataramI.SiegelR.L.TorreL.A.JemalA.Global" exact="cancer" post="statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide"/>
 <result pre="ItalyJ. Vet. Intern. Med.20082297698410.1111/j.1939-1676.2008.0133.x18564221 78.KelseyJ.L.MooreA.S.GlickmanL.T.Epidemiologic studies of risk factors for" exact="cancer" post="in pet dogsEpidemiol. Rev.19982020421710.1093/oxfordjournals.epirev.a0179819919439 79.SleeckxN.de RoosterH.Veldhuis KroezeE.J.Van GinnekenC.Van BrantegemL.Canine"/>
 <result pre="for application in veterinary oncologyMol. Ther.20142298699810.1038/mt.2014.724448161 83.GentschevI.StritzkerJ.HofmannE.WeibelS.YuY.A.ChenN.ZhangQ.BullerdiekJ.NolteI.SzalayA.A.Use of an oncolytic" exact="vaccinia virus" post="for the treatment of canine breast cancer in nude"/>
 <result pre="of an oncolytic vaccinia virus for the treatment of canine" exact="breast cancer" post="in nude mice: Preclinical development of a therapeutic agentCancer"/>
 <result pre="an oncolytic vaccinia virus for the treatment of canine breast" exact="cancer" post="in nude mice: Preclinical development of a therapeutic agentCancer"/>
 <result pre="Canine Cancer TherapyViruses201574075409210.3390/v707281126205404 85.HwangC.C.UmekiS.IgaseM.CoffeyM.NoguchiS.OkudaM.MizunoT.The effects of oncolytic reovirus in canine" exact="lymphoma" post="cell linesVet. Comp. Oncol.201614 Suppl 1617310.1111/vco.1212425319493 86.ShojiK.YonedaM.FujiyukiT.AmagaiY.TanakaA.MatsudaA.OgiharaK.NayaY.IkedaF.MatsudaH.et al.Development of"/>
 <result pre="Suppl 1617310.1111/vco.1212425319493 86.ShojiK.YonedaM.FujiyukiT.AmagaiY.TanakaA.MatsudaA.OgiharaK.NayaY.IkedaF.MatsudaH.et al.Development of new therapy for canine mammary" exact="cancer" post="with recombinant measles virusMol. Ther. Oncolytics201631502210.1038/mto.2015.2227119113 87.HwangC.C.IgaseM.SakuraiM.HaraguchiT.TaniK.ItamotoK.ShimokawaT.NakaichiM.NemotoY.NoguchiS.et al.Oncolytic reovirus"/>
 <result pre="al.Development of new therapy for canine mammary cancer with recombinant" exact="measles" post="virusMol. Ther. Oncolytics201631502210.1038/mto.2015.2227119113 87.HwangC.C.IgaseM.SakuraiM.HaraguchiT.TaniK.ItamotoK.ShimokawaT.NakaichiM.NemotoY.NoguchiS.et al.Oncolytic reovirus therapy: Pilot study"/>
 <result pre="spontaneously occurring tumoursVet. Comp. Oncol.20181622923810.1111/vco.1236129076241 88.DeryckeM.S.PambuccianS.E.GilksC.B.KallogerS.E.GhidoucheA.LopezM.BlissR.L.GellerM.A.ArgentaP.A.HarringtonK.M.et al.Nectin 4 overexpression in" exact="ovarian cancer" post="tissues and serum: Potential role as a serum biomarkerAm."/>
 <result pre="occurring tumoursVet. Comp. Oncol.20181622923810.1111/vco.1236129076241 88.DeryckeM.S.PambuccianS.E.GilksC.B.KallogerS.E.GhidoucheA.LopezM.BlissR.L.GellerM.A.ArgentaP.A.HarringtonK.M.et al.Nectin 4 overexpression in ovarian" exact="cancer" post="tissues and serum: Potential role as a serum biomarkerAm."/>
 <result pre="marker PVRL4 (nectin 4) is an epithelial cell receptor for" exact="measles" post="virusPLoS Pathog.20117e100224010.1371/journal.ppat.100224021901103 90.TakanoA.IshikawaN.NishinoR.MasudaK.YasuiW.InaiK.NishimuraH.ItoH.NakayamaH.MiyagiY.et al.Identification of nectin-4 oncoprotein as a"/>
 <result pre="factor in the late-phase of the tumor regression process upon" exact="vaccinia virus" post="infectionBMC Cancer2011116810.1186/1471-2407-11-6821320309 93.BreitbachC.J.PatersonJ.M.LemayC.G.FallsT.J.McGuireA.ParatoK.A.StojdlD.F.DaneshmandM.SpethK.KirnD.et al.Targeted inflammation during oncolytic virus therapy"/>
 <result pre="Inhibition of Canine mammary carcinoma xenografts following treatment with oncolytic" exact="vaccinia virus" post="GLV-1h68J. Oncol.2010201073690710.1155/2010/73690720631910 95.GentschevI.AdelfingerM.JosupeitR.RudolphS.EhrigK.DonatU.WeibelS.ChenN.G.YuY.A.ZhangQ.et al.Preclinical evaluation of oncolytic vaccinia virus"/>
 <result pre="oncolytic vaccinia virus GLV-1h68J. Oncol.2010201073690710.1155/2010/73690720631910 95.GentschevI.AdelfingerM.JosupeitR.RudolphS.EhrigK.DonatU.WeibelS.ChenN.G.YuY.A.ZhangQ.et al.Preclinical evaluation of oncolytic" exact="vaccinia virus" post="for therapy of canine soft tissue sarcomaPLoS ONE20127e3723910.1371/journal.pone.003723922615950 96.DaltonD.K.Pitts-MeekS.KeshavS.FigariI.S.BradleyA.StewartT.A.Multiple"/>
 <result pre="complexes using a high-affinity T-cell receptorGene Ther.2004111234123910.1038/sj.gt.330228615215883 103.BucheitA.D.KumarS.GroteD.M.LinY.von MesslingV.CattaneoR.B.FieldingA.K.An oncolytic" exact="measles" post="virus engineered to enter cells through the CD20 antigenMol."/>
 <result pre="the CD20 antigenMol. Ther.20037627210.1016/S1525-0016(02)00033-312573619 104.HammondA.L.PlemperR.K.ZhangJ.SchneiderU.RussellS.J.CattaneoR.Single-chain antibody displayed on a recombinant" exact="measles" post="virus confers entry through the tumor-associated carcinoembryonic antigenJ. Virol.2001752087209610.1128/JVI.75.5.2087-2096.200111160713"/>
 <result pre="virus confers entry through the tumor-associated carcinoembryonic antigenJ. Virol.2001752087209610.1128/JVI.75.5.2087-2096.200111160713 105.PengK.W.DonovanK.A.SchneiderU.CattaneoR.LustJ.A.RussellS.J.Oncolytic" exact="measles" post="viruses displaying a single-chain antibody against CD38, a myeloma"/>
 <result pre="antibody against CD38, a myeloma cell markerBlood20031012557256210.1182/blood-2002-07-219512433686 106.OngH.T.TrejoT.R.PhamL.D.ObergA.L.RussellS.J.PengK.W.Intravascularly administered RGD-displaying" exact="measles" post="viruses bind to and infect neovessel endothelial cells in"/>
 <result pre="to and infect neovessel endothelial cells in vivoMol. Ther.2009171012102110.1038/mt.2009.3919277014 107.HallakL.K.MerchanJ.R.StorgardC.M.LoftusJ.C.RussellS.J.Targeted" exact="measles" post="virus vector displaying echistatin infects endothelial cells via alpha(v)beta3"/>
 <result pre="signaling lymphocyte activation molecule as a novel oncolytic virus for" exact="breast cancer" post="treatmentGene Ther.20132033834710.1038/gt.2012.4422717740 109.LeonardV.H.HodgeG.Reyes-Del ValleJ.McChesneyM.B.CattaneoR.Measles virus selectively blind to signaling"/>
 <result pre="lymphocyte activation molecule as a novel oncolytic virus for breast" exact="cancer" post="treatmentGene Ther.20132033834710.1038/gt.2012.4422717740 109.LeonardV.H.HodgeG.Reyes-Del ValleJ.McChesneyM.B.CattaneoR.Measles virus selectively blind to signaling"/>
 <result pre="112.PfankucheV.M.Sayed-AhmedM.ContiosoV.B.SpitzbarthI.RohnK.UlrichR.DeschlU.KalkuhlA.BaumgartnerW.PuffC.Persistent morbillivirus infection leads to altered cortactin distribution in histiocytic" exact="sarcoma" post="cells with decreased cellular migration capacityPLoS ONE201611e016751710.1371/journal.pone.016751727911942 113.BieringerM.HanJ.W.KendlS.KhosraviM.PlattetP.Schneider-SchauliesJ.Experimental adaptation"/>
 <result pre="virusJ. Virol.2014884423443310.1128/JVI.03676-1324501402 115.SaxenaM.VanT.T.H.BairdF.J.ColoeP.J.SmookerP.M.Pre-existing immunity against vaccine vectors--friend or foe?Microbiology201315911110.1099/mic.0.049601-023175507 116.HastieE.GrdzelishviliV.Z.Vesicular" exact="stomatitis" post="virus as a flexible platform for oncolytic virotherapy against"/>
 <result pre="of nectin4 binding compromises CD46 usage by a hybrid vesicular" exact="stomatitis" post="virus/measles virusJ. Virol.2014882195220410.1128/JVI.02628-1324335299 118.GroteD.CattaneoR.FieldingA.K.Neutrophils contribute to the measles virus-induced"/>
 <result pre="hybrid vesicular stomatitis virus/measles virusJ. Virol.2014882195220410.1128/JVI.02628-1324335299 118.GroteD.CattaneoR.FieldingA.K.Neutrophils contribute to the" exact="measles" post="virus-induced antitumor effect: Enhancement by granulocyte macrophage colony-stimulating factor"/>
 <result pre="macrophage colony-stimulating factor expressionCancer Res.2003636463646814559838 119.GrossardtC.EngelandC.E.BossowS.HalamaN.ZaouiK.LeberM.F.SpringfeldC.JaegerD.von KalleC.UngerechtsG.Granulocyte-macrophage colony-stimulating factor-armed oncolytic" exact="measles" post="virus is an effective therapeutic cancer vaccineHum. Gene Ther.20132464465410.1089/hum.2012.20523642239"/>
 <result pre="KalleC.UngerechtsG.Granulocyte-macrophage colony-stimulating factor-armed oncolytic measles virus is an effective therapeutic" exact="cancer" post="vaccineHum. Gene Ther.20132464465410.1089/hum.2012.20523642239 120.LiH.PengK.W.DingliD.KratzkeR.A.RussellS.J.Oncolytic measles viruses encoding interferon beta"/>
 <result pre="virus is an effective therapeutic cancer vaccineHum. Gene Ther.20132464465410.1089/hum.2012.20523642239 120.LiH.PengK.W.DingliD.KratzkeR.A.RussellS.J.Oncolytic" exact="measles" post="viruses encoding interferon beta and the thyroidal sodium iodide"/>
 <result pre="interferon beta and the thyroidal sodium iodide symporter gene for" exact="mesothelioma" post="virotherapyCancer Gene Ther.20101755055810.1038/cgt.2010.1020379224 121.BackhausP.S.VeinaldeR.HartmannL.DunderJ.E.JeworowskiL.M.AlbertJ.HoylerB.PothT.JagerD.UngerechtsG.et al.Immunological effects and viral gene"/>
 <result pre="effects and viral gene expression determine the efficacy of oncolytic" exact="measles" post="vaccines encoding IL-12 or IL-15 agonistsViruses20191191410.3390/v1110091431623390 122.QuezadaS.A.PeggsK.S.Exploiting CTLA-4, PD-1"/>
 <result pre="Cancer Res.2013195300530910.1158/1078-0432.CCR-13-014324089443 124.EngelandC.E.GrossardtC.VeinaldeR.BossowS.LutzD.KaufmannJ.K.ShevchenkoI.UmanskyV.NettelbeckD.M.WeichertW.et al.CTLA-4 and PD-L1 checkpoint blockade enhances oncolytic" exact="measles" post="virus therapyMol. Ther.2014221949195910.1038/mt.2014.16025156126 125.ArefS.BaileyK.FieldingA.Measles to the rescue: A review"/>
 <result pre="therapyMol. Ther.2014221949195910.1038/mt.2014.16025156126 125.ArefS.BaileyK.FieldingA.Measles to the rescue: A review of oncolytic" exact="measles" post="virusViruses2016829410.3390/v8100294 Figure 1 Reverse genetic system for the recovery"/>
 <result pre="Antigen N-P Protection of dogs from challenge with CDV and" exact="cutaneous leishmaniasis" post="[69] Wild-type strain A75/17-V EGFP 3′ Leader-N NFAE [29]"/>
 <result pre="N-P Protection of dogs from challenge with CDV and cutaneous" exact="leishmaniasis" post="[69] Wild-type strain A75/17-V EGFP 3′ Leader-N NFAE [29]"/>
 <result pre="mice and enhancing the production of CDV NAb [71] RABV-G:" exact="rabies" post="virus G protein; NFAE: no foreign antigen expressed; NAb:"/>
 <result pre="Type Tumor Cells Oncolytic Effects In Vivo Ref. Onderstepoort Canine" exact="lymphoma" post="CLL-1390, CLGL-90, 17–71 ND [16] Lederle Human cervical tumor"/>
 <result pre="Lederle Human cervical tumor HeLa ND [18] Onderstepoort Canine histiocytic" exact="sarcoma" post="CCT, DH82 Decreasing blood vessel generation with a lower"/>
</results>
